EORTC Presentations at ASCO 2017 in Chicago
24 May 2017
EORTC will be presenting one oral abstract session, three abstracts in poster sessions and two publications at the ASCO Annual Meeting (June 2-6, 2017) in Chicago.
Oral presentations
- Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion. (Abstract 2009)
Citation: J Clin Oncol 35, 2017
Session: Maximizing the Approach to Central Nervous System Tumors
Time: Saturday June 3, 3:00 to 4:30 PM
Location: S102
Poster sessions
- EORTC1527/JCOG1609int: diffusion-weighted magnetic resonance imaging (DW-MRI) assessment of liver metastasis to improve surgical planning (DREAM) (Abstract TPS3633)
Citation: J Clin Oncol 35, 2017
Session: Gastrointestinal (Colorectal) Cancer
Time: Saturday June 3, 8:00 to 11:30 AM
Location: Hall A
Authors: Kozo Kataoka, Carmela Aves Caballero, Laurence Collette, Kenichi Nakamura, Yoji Kishi, Patrick Starlinger, Hiroaki Onaya, Takeshi Suto, Michel Ducreux, Yasuhiro Shimada, Sabine Tejpar, Laura Rubbia-brandt, Gina Brown, Manabu Shiozawa, Serge Evrard - Standard anthracycline-based vs. Docetaxel-Capecitabine in early breast cancer: results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial. (Abstract 516)
Citation: J Clin Oncol 35, 2017
Session: Breast Cancer – Local/ Regional/ Adjuvant
Time: Sunday June 4, 8:00 to 11:30 AM
Location: Hall A
Session: Breast Cancer – Local/ Regional/ Adjuvant
Time: Sunday June 4, 11:30 AM to 12:45 PM
Location: Hall D2
Authors: Fatima Cardoso, Martine J. Piccart-Gebhart, Emiel J. Rutgers, Saskia Litière, Laura Van’t Veer, Giuseppe Viale, Jean-Yves Pierga, Franchette W.P.J. van den Berkmortel, Etienne Brain, Patricia Gomez, Theodora Goulioti, Susan Knox, Elisabeth Luporsi, Ulrike Nitz, Isabel T Rubio, Lisette Stork, Peter Vuylsteke, Konstantinos Tryfonidis, Jan Bogaerts, Suzette delaloge - RECIST 1.1 validated not only for cytotoxic agents but also for targeted cancer agents (TCA): results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database (Abstract 2534)
Citation: J Clin Oncol 35, 2017
Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Time: Monday June 5, 8:00 to 11:30 AM
Location: Hall A
Authors: Saskia Litière, Gaëlle Isaac, Elisabeth De Vries, Jan Bogaerts, Alice Chen, Janet Dancey, Robert Ford, Stephen Gwyther, Otto Hoekstra, Erich Huang, Nancy Lin, Yan Liu, Sumithra Mandrekar, Lawrence H Schwartz, Lalitha Shankar, Patrick Therasse, Lesley Seymour, On behalf of the RECIST Working Group
Publication-only abstracts
- Prognostic impact of primary tumor location in advanced urothelial carcinoma; the EORTC series. (Abstract e16034)
Citation: J Clin Oncol 35, 2017
Authors: Marco Moschini, Shahrokh F. Shariat, Maria De Santis, Joaquim Bellmunt, Cora N. Sternberg, Bertrand F. Tombal, Laurence Collette, Morgan Roupret; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Medical University of Vienna, Vienna, Austria; LBI-ACR Vienna, Kaiser Franz Josef Hospital, Center for Oncology and Hematology, Vienna, Austria; Dana-Farber Cancer Institute, Boston, MA; San Camillo Forlanini Hospital, Rome, Italy; Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; EORTC, Brussels, Belgium; Urology University Paris 6, Paris, France - Cancer events in Belgian nursing home residents (NHR): An EORTC prospective cohort study. (Abstract e13066)
Citation: J Clin Oncol 35, 2017
Authors: Hans Wildiers, Monique Elseviers, Murielle E. Mauer, Jonas de Wolf, Edith Bastiaens, Sigrid Hatse, Marije Hamaker, Frank Buntinx, Jan de Lepeleire, Geert Uytterschaut, Konstantinos Tryfonidis, Maryska Janssen-Heijnen; University Hospitals Leuven, Leuven, Belgium; Centre for Research and Innovation in Care (CRIC), Faculty of Medicine and Health Care Sciences, University of Antwerp, Antwerp, Belgium; EORTC, Brussels, Belgium; Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, Leuven, Belgium; Department of Geriatric Medicine, Utrecht, Netherlands; Department of General Practice, Universities of Leuven and Maastricht, Leuven, Belgium; Departement of General Practice and University Psychiatric Hospital KU Leuven, Leuven, Belgium; Armonea, Belgium, Mechelen, Belgium; Department of Clinical Epidemiology, VieCuri Medical Centre, and the Maastricht University Medical Center+, GROW School for Oncology and Developmental Biology, Maastricht, Netherlands
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023